The importance of residual effects when choosing a hypnotic: The unique profile of zaleplon

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 3, Issue 2, 2001, Pages 53-60

  Zammit, Gary K ^a   Kramer, Jeffrey A ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b Ingenix Clinical Communications Pharmaceutical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 20844439088     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v03n0202     Document Type: Article

References (69)

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment: prevalence and correlates. Arch Gen Psychiatry 1985;42:225-232
2. Kuppermann M, Lubeck DP, Mazonson PD, et al. Sleep problems and their correlates in a working population J Gen Intern Med 1995;10:25-32
3. Klink ME, Quan SF, Kaltenborn WT, et al. Risk factors associated with complaints of insomnia in a general adult population: influence of previous complaints of insomnia. Arch Intern Med 1992;152:1634-1637
4. National Heart, Lung, and Blood Institute Working Group on Insomnia. Insomnia: Assessment and Management in Primary Care. Bethesda, Md: National Institutes of Health; 1998. No. 98-4088
5. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA 1989;262:1479-1484
6. Johnson EO. Sleep in America: 1999 - Results From the National Sleep Foundation's 1999 Omnibus Sleep Poll. Washington, DC: National Sleep Foundation; 1999
7. Newman AB, Enright PL, Manolio TA, et al. Sleep disturbance, psychosocial correlates, and cardiovascular disease in 5201 older adults: the Cardiovascular Health Study. J Am Geriatr Soc 1997;45:1-7
8. Lavie P. Sleep habits and sleep disturbances in industrial workers in Israel: main findings and some characteristics of workers complaining of excessive daytime sleepiness. Sleep 1981;4:147-158
9. Kripke DF, Simons RN, Garfinkel L, et al. Short and long sleep and sleeping pills: is increased mortality associated? Arch Gen Psychiatry 1979;36:103-116
10. Pollak CP, Perlick D, Linsner JP, et al. Sleep problems in the community elderly as predictors of death and nursing home placement. J Community Health 1990;15:123-135
11. Balter MB, Uhlenhuth EH. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992;53(12, suppl):34-39
12. Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994;17:84-93
13. Walsh JK, Engelhardt CL. The direct economic costs of insomnia in the United States for 1995. Sleep 1999;22(suppl 2):S386-S393
14. Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep 1991;14: 392-398
15. Simon GE, VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997;154:1417-1423
16. Stoller MK. Economic effects of insomnia. Clin Ther 1994;16:873-896
17. Everitt DE, Avorn J, Baker MW. Clinical decision-making in the evaluation and treatment of insomnia. Am J Med 1990;89:357-362
18. Hauri PJ. Insomnia. Clin Chest Med 1998;19:157-168
19. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry 1994;151:1172-1180
20. Chesson AL Jr, Anderson WM, Littner M, et al. Practice parameters for the nonpharmacologic treatment of chronic insomnia: an American Academy of Sleep Medicine report. Sleep 1999;22:1128-1133
21. Nowell PD, Buysse DJ, Morin CM, et al. Effective treatments for selected sleep disorders. In: Nathan PE, Gorman JM, eds. A Guide to Treatments That Work. New York, NY: Oxford University Press; 1998:531-542
22. Nowell PD, Mazumdar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-2177
23. Schweitzer PK, Walsh JK. Ten-year trends in the pharmacological treatment of insomnia [abstract 209.C]. Sleep 1998;21(suppl):247
24. Roehrs TA. Sedating drugs without hypnotic indications. In: Goldberg JR, ed. The Pharmacological Management of Insomnia. Washington, DC: National Sleep Foundation; 1996:35-42
25. Ware JC. Tricyclic antidepressants in the treatment of insomnia. J Clin Psychiatry 1983;44(9 pt 2):25-28
26. Greenblatt DJ, Harmatz JS, von Moltke LL, et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998;64:553-561
27. Beer B, Clody DE, Mangano R, et al. A review of the preclinical development of zaleplon, a novel non-benzodiazepine hypnotic for the treatment of insomnia. CNS Drug Rev 1997;3:207-224
28. Greenblatt DJ, Shader RI, Divoll M, et al. Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. J Clin Psychiatry 1984;45:192-195
29. Greenblatt DJ, Harmatz JS, Shapiro L, et al. Sensitivity to triazolam in the elderly. N Engl J Med 1991;324:1691-1698
30. Farney RJ, Walker JM. Office management of common sleep-wake disorders. Med Clin North Am 1995;79:391-414
31. Halcion (triazolam tablets). Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics; 2000:2461-2463
32. Ambien (zolpidem tartrate). Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics; 2000:2884-2888
33. Dement WC. Overview of the efficacy and safety of benzodiazepine hypnotics using objective methods [introduction]. J Clin Psychiatry 1991;52(9, suppl):27-30
34. Walsh JK, Fry J, Erwin CW, et al. Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 1998;16:347-354
35. Elie R, Rüther E, Farr I, et al. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 1999;60:536-544
36. Dietrich B, Farr I. Zaleplon: dose-response evaluation in primary insomnia [abstract 116]. Sleep Res 1995;24A:116
37. Erwin CW, Fry JM, Richardson GS, et al. A multicenter, placebo-controlled, polysomnographic study of zaleplon in elderly patients with chronic insomnia [abstract PW16095]. Presented at the 21st Collegium Internationale Neuro-Psychopharmacologicum; July 12-16, 1998; Glasgow Scotland
38. Walsh JK, Ancoli-Israel S, Mangano R, et al. Zaleplon 5 mg and 10 mg for the treatment of elderly primary insomniacs [abstract C561.C]. Sleep 1999;22(suppl 1):S241-S342
39. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs, zaleplon and zolpidem. Eur J Pharmacol 1996;313:35-42
40. A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:139-148
41. Vanover KE, Mangano R, Barrett JE CL 284,846, a novel sedativehypnotic: evaluation of its metabolites for pharmacological activity in vitro and in vivo. Drug Dev Res 1994;33:39-45
42. Darwish M. The effects of age and gender on the pharmacokinetics of zaleplon [abstract]. Eur Neuropsychopharmacol 1999;9(suppl 5):S360
43. Kaplan HI, Sadock BJ. Normal sleep. In: Gay SM, ed. Concise Textbook of Clinical Psychiatry. Baltimore, Md: Williams & Wilkins; 1996:279-281
44. Obermeyer WH, Benca RM. Effects of drugs on sleep. Neurol Clin 1996;14:827-840
45. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practices of Sleep Medicine. 2nd ed. Philadelphia, Pa: WB Saunders; 1994:16-25
46. Berlin I, Warot D, Hergueta T, et al. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 1993;13:100-106
47. Roehrs T, Merlotti L, Zorick F, et al. Sedative, memory, and performance effects of hypnotics. Psychopharmacology (Berl) 1994;116:130-134
48. Beer B, Ieni JR, Wu WH, et al. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic. J Clin Pharmacol 1994;34:335-344
49. Troy SM, Lucki I, Unruh MA, et al. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol 2000;20:328-337
50. Allen D, Curran HV, Lader M. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 1993;45:313-320
51. Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry 1992;53(6 suppl):14-18
52. Johnson LC, Chernik DA. Sedative-hypnotics and human performance. Psychopharmacology (Berl) 1982;76:101-113
53. Roehrs T, Kribbs N, Zorick F, et al. Hypnotic residual effects of benzodiazepines with repeated administration. Sleep 1986;9:309-316
54. Bliwise D, Seidel W, Karacan I, et al. Daytime sleepiness as a criterion in hypnotic medication trials: comparison of triazolam and flurazepam. Sleep 1983;6:156-163
55. Kramer M, Schoen LS. Problems in the use of long-acting hypnotics in older patients. J Clin Psychiatry 1984;45:176-177
56. Wang P, Bohn R, Glynn R, et al. Hip fracture risks with sedative hypnotic use in elderly patients [Abstract 022]. Pharmacoepidemiol Drug Saf 1999;8(suppl 2):S87
57. Ray WA, Griffin MR, Schaffner. W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-369
58. Barbone F, McMahon AD, DaVey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998;352:1331-1336
59. Neutel CI. Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 1995;5:239-244
60. Danjou P Paty I, Fruncillo R, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol 1999;48:367-374
61. Dietrich B, Emilien G, Salinas E. Zaleplon does not produce residual sedation in a phase-advance model of transient insomnia [abstract 133]. J Sleep Res 1998;7(suppl 2):67
62. Vermeeren A, Danjou PE, O'Hanlon JE Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol Clin Exp 1998;13:S98-S107
63. Walsh JK, Pollak CP, Scharf MB, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia. Clin Neuropharmacol 2000;23:17-21
64. Ware JC, Allen R, Scharf MB, et al. An evaluation of residual sedation following nighttime administration of 10 or 20 mg of zaleplon, 30 mg of flurazepam, or placebo in healthy subjects [abstract 313. C]. Sleep 1998;21:263
65. Sonata (zaleplon) capsules. Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics; 2000:3319-3323
66. Zammit G. Zaleplon vs. zolpidem: differences in next-day residual sedation after middle-of-the-night administration [abstract]. Presented at the 15th Congress of the European Sleep Research Society; Sept 12-16,2000; Istanbul, Turkey
67. Walsh JK, Scharf MB, Pollak C, et al. Lack of residual sedation following middle-of-the-night zaleplon administration in sleep maintenance insomnia [abstract 211.C]. Sleep 1998;21(suppl):247
68. Hedner J, Mangano R. Zaleplon provides safe long-term treatment of insomnia in the elderly [abstract P.6.048]. Eur Neuropsychopharmacol 1999;9(suppl 5):S362
69. Scharf M. The safety of long-term treatment of insomnia with zaleplon [abstract]. Eur Neuropsychopharmacol 1999;9(suppl 5):S360-S361